X
[{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and MedinCell Announce Results for Registration Trial of Extended-Release Subcutaneous Injectable Risperidone for Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"January 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva to Present New Data from Growing Mental Health Portfolio at Psych Congress 2021","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000\/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with Schizophrenia","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"MedinCell","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Teva and MedinCell Receive Complete Response Letter for TV-46000\/mdc-IRM","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"April 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Royalty Pharma","pharmaFlowCategory":"D","amount":"$125.0 million","upfrontCash":"Undisclosed","newsHeadline":"Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Sanofi","pharmaFlowCategory":"D","amount":"$1,500.0 million","upfrontCash":"$500.0 million","newsHeadline":"Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Phase III","country":"ISRAEL","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Small molecule","graph2":"Teva Pharmaceutical Industries"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
The collaboration aims to co-develop and co-commercialize asset TEV’574, a novel anti-TL1A therapy, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn's Disease, two types of inflammatory bowel disease.
Lead Product(s):
Olanzapine
Therapeutic Area: Psychiatry/Psychology
Product Name: TEV-‘749
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Sanofi
Deal Size: $1,500.0 million
Upfront Cash: $500.0 million
Deal Type: Collaboration
November 30, 2023
Details:
The collaboration aims to accelerate the clinical research program for Teva’s TEV-‘749 (olanzapine), a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia.
Lead Product(s):
Olanzapine
Therapeutic Area: Psychiatry/Psychology
Product Name: TEV-‘749
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Royalty Pharma
Deal Size: $125.0 million
Upfront Cash: Undisclosed
Deal Type: Collaboration
November 13, 2023
Details:
The application included Phase 3 data from two pivotal studies, for TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) for the treatment of schizophrenia.
Lead Product(s):
Risperidone
Therapeutic Area: Psychiatry/Psychology
Product Name: TV-46000
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
MedinCell
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 19, 2022
Details:
Risperidone extended-release injectable suspension is an antipsychotic medicine and dopamine D2, 5-HT2A, alpha1-adrenoceptor, and histamine-1 receptor antagonist used for subcutaneous use as a treatment in patients (ages 13-65 years) with schizophrenia.
Lead Product(s):
Risperidone
Therapeutic Area: Psychiatry/Psychology
Product Name: mdc-IRM
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 30, 2021
Details:
mdc-IRM, a risperidone extended-release injectable suspension for the treatment of patients with schizophrenia. AUSTEDO® is a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of chorea associated with Huntington’s disease.
Lead Product(s):
Risperidone
Therapeutic Area: Psychiatry/Psychology
Product Name: mdc-IRM
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 21, 2021
Details:
Data from the study showed that patients who received risperidone had a statistically significant delay in time to relapse as compared to placebo, thus meeting the primary endpoint.
Lead Product(s):
Risperidone
Therapeutic Area: Psychiatry/Psychology
Product Name: TV46000-CNS-30072
Highest Development Status: Phase III
Product Type: Small molecule
Partner/Sponsor/Collaborator:
MedinCell
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
January 07, 2021